Ophthalmology Drugs
309 FDA-approved drugs
TheraRadar tracks 309 FDA-approved ophthalmology drugs from 89 companies across 21 drug classes, led by Novartis, with 287 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Ophthalmology.
Ophthalmology Approvals by Year
'15
7
'16
5
'17
5
'18
5
'19
7
'20
5
'21
5
'22
12
'23
5
'24
6
'25
1
'26
Recent Ophthalmology Drug Approvals
YUVEZZI
BRIMONIDINE TARTRATE
presbyopia in adults...
2026-01-28
VISUS
alpha-adrenergic receptorscholinergic receptors
NUFYMCO
RANIBIZUMAB-LEYK
2025-12-18
FORMYCON AG
LOTEPREDNOL ETABONATE AND TOBRAMYCIN
LOTEPREDNOL ETABONATE
ster...
2025-12-10
ALEMBIC
Phospholipase A2
ZOLYMBUS
BIMATOPROST
the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular ...
2025-09-09
THEA PHARMA
VIZZ
ACECLIDINE HYDROCHLORIDE
presbyopia in adults...
2025-07-31
LENZ THERAP
Muscarinic receptor
TRYPTYR
ACOLTREMON
the signs and symptoms of dry eye disease...
2025-05-28
Novartis
TRPM8
LATANOPROSTENE BUNOD
LATANOPROSTENE BUNOD
the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertens...
2025-04-29
GLAND
ENZEEVU
AFLIBERCEPT-ABZV
2024-08-09
Novartis
OPUVIZ
AFLIBERCEPT-YSZY
2024-05-20
SAMSUNG BIOEPIS CO LTD
YESAFILI
AFLIBERCEPT-JBVF
2024-05-20
BIOCON BIOLOGICS INC
LUMIFY PRESERVATIVE FREE
BRIMONIDINE TARTRATE
2024-04-19
BAUSCH AND LOMB INC
FLUOROMETHOLONE
FLUOROMETHOLONE
corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior ...
2024-01-09
Novartis
IDOSE TR
TRAVOPROST
the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hyp...
2023-12-13
GLAUKOS
FP prostanoid receptor
QLOSI
PILOCARPINE HYDROCHLORIDE
presbyopia in adults...
2023-10-17
ORASIS PHARMS
Muscarinic receptor
RYZUMVI
PHENTOLAMINE MESYLATE
pharmacologically-induced mydriasis produced by adrenergic agonists (e...
2023-09-25
FAMYGEN LIFE SCI
alpha-1 adrenergic receptoralpha-2 adrenergic receptor
FLUORESCEIN SODIUM
FLUORESCEIN SODIUM
INDICATIONS For testing tear film stability by determining the fluorescein break-up time (FBUT)...
2023-09-25
BPI LABS
LIFITEGRAST
LIFITEGRAST
2023-08-04
INGENUS PHARMS LLC
IZERVAY
AVACINCAPTAD PEGOL SODIUM
geographic atrophy (GA) secondary to age-related macular degeneration (AMD)...
2023-08-04
ASTELLAS
Complement C5
XDEMVY
LOTILANER
Demodex blepharitis...
2023-07-24
TARSUS
GABA-gated chloride channel
ALCAFTADINE
ALCAFTADINE
2023-06-23
ALEMBIC
Showing the 20 most recent of 309 ophthalmology drugs. View all 309 →
Top Ophthalmology Companies
Ophthalmology Active Trials by Indication
287 active trials — the forward pipeline, not just approvals.
All competitive landscapes →Ophthalmology Drug Classes
Corticosteroid 13
Prostaglandin Analog 12
Calcineurin Inhibitor Immunosuppressant 5
Aminoglycoside Antibacterial 3
Vascular Endothelial Growth Factor Inhibitor 3
Carbonic Anhydrase Inhibitor 3
Quinolone Antimicrobial 3
Ectoparasiticide 1
Semifluorinated Alkane 1
Complement Inhibitor 1
Ophthalmology at a Glance
- Total Drugs
- 309
- Companies
- 89
- Drug Classes
- 21
- Active Trials
- 287
- Latest Approval
- 2026-01-28